Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median Effective Dose of Remimazolam for Procedural Sedation in Hip Arthroplasty and Impact of Frailty
ChiCTR2500113622Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Shantou University Medical College
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam in hip fracture and Fragility (2 arms), sponsored by The First Affiliated Hospital of Shantou University Medical College. Primary endpoint: Effective procedural sedation. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
hip fractureFragility
Beyond the preview
Go deeper on ChiCTR2500113622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113622.